• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 39-53 of 6,212 results

No. 353 MEMORANDUM Opinion and Order signed by the Honorable Mary M. Rowland on 12/27/2023

Document In RE: Hair Relaxer Marketing, Sales Practices, And Products Liability Litigation, 1:23-cv-00818, No. 353 (N.D.Ill. Dec. 27, 2023)
A parent-subsidiary relationship weighs in favor of closeness “because of the [common] ownership situation, there often exists some intermingling of directors, officers, or employees, or business relations.” In re Zantac (Ranitidine) Products Liab.
But L’Oréal S.A. makes information permanently available to L’Oréal USA to (1) enable its Research, Innovation and Technology Department to implement “cosmeto- vigilence and the quality of the formulas used within products” and (2) to provide documents and guides to ensure targets and goals are achieved.
Involvement in Litigation: Plaintiffs rely heavily on the fact that L’Oréal U.S.A. has already produced documents from the possession of L’Oréal S.A. On September 14, 2023, L’Oréal U.S.A. responded to an interrogatory seeking a comprehensive list of the subsidiary company’s hair relaxer products with data obtained from L’Oréal S.A. [313] at 8-9.
But the Court does not need a specific showing of burden to find that asking L’Oréal S.A., a behemoth multi-national corporation, to search and produce its internal governance records over multiple decades would generate significant costs.
The Court agrees that producing dates of sale across a large time is not proportional to the issues of liability in this case, especially as foreign regulatory communications will reveal pertinent timeframes.
cite Cite Document
Analyze

No. 5274

Document In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 5274 (N.D.Ohio Dec. 14, 2023)

cite Cite Document
Analyze

No. 291

Document In RE: Hair Relaxer Marketing, Sales Practices, And Products Liability Litigation, 1:23-cv-00818, No. 291 (N.D.Ill. Nov. 13, 2023)

cite Cite Document
Analyze

No. 320

Document Lester E. Cox Medical Centers et al v. Amneal Pharmaceuticals, LLC et al, 6:22-cv-03192, No. 320 (W.D.Mo. Sep. 28, 2023)

cite Cite Document
Analyze

No. 5186

Document In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 5186 (N.D.Ohio Sep. 13, 2023)

cite Cite Document
Analyze

No. 5175

Document In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 5175 (N.D.Ohio Sep. 7, 2023)

cite Cite Document
Analyze

No. 5172

Document In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 5172 (N.D.Ohio Sep. 6, 2023)

cite Cite Document
Analyze

No. 5161

Document In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 5161 (N.D.Ohio Aug. 28, 2023)

cite Cite Document
Analyze

No. 5159

Document In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 5159 (N.D.Ohio Aug. 24, 2023)

cite Cite Document
Analyze

No. 5148

Document In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 5148 (N.D.Ohio Aug. 16, 2023)

cite Cite Document
Analyze

No. 5131

Document In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 5131 (N.D.Ohio Jul. 25, 2023)

cite Cite Document
Analyze

No. 258

Document Lester E. Cox Medical Centers et al v. Amneal Pharmaceuticals, LLC et al, 6:22-cv-03192, No. 258 (W.D.Mo. Jul. 18, 2023)

cite Cite Document
Analyze

No. 5100

Document In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 5100 (N.D.Ohio Jul. 6, 2023)

cite Cite Document
Analyze

No. 5060

Document In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 5060 (N.D.Ohio Jun. 8, 2023)

cite Cite Document
Analyze

No. 5009

Document In Re: National Prescription Opiate Litigation, 1:17-md-02804, No. 5009 (N.D.Ohio Apr. 21, 2023)

cite Cite Document
Analyze
<< 1 2 3 4 5 6 7 ... >>